Natalia V. Khachanova

Moscow, MOW, Russian Federation

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications

New opportunities in the treatment of patients with multiple sclerosis (Resolution of the Council of Experts on April 23, 2022, Moscow, JSC «BIOCAD»)

New opportunities in the treatment of patients with multiple sclerosis (Resolution of the Council of Experts on April 23, 2022, Moscow, JSC «BIOCAD»)

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Published: August 01, 2022

Long-term treatment for multiple sclerosis with interferon beta-1b. Outcomes of an open, retrospective, observational study

Long-term treatment for multiple sclerosis with interferon beta-1b. Outcomes of an open, retrospective, observational study

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Published: August 01, 2022

Validation of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) in the Russian Population.

Validation of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) in the Russian Population.

Journal: Journal of the International Neuropsychological Society : JINS
Published: June 16, 2021

Updated recommendations of the Council of Experts on the use and safety of alemtuzumab (Lemtrada)

Updated recommendations of the Council of Experts on the use and safety of alemtuzumab (Lemtrada)

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Published: April 24, 2020

New directions of immunocorrection in multiple sclerosis

New directions of immunocorrection in multiple sclerosis

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Published: April 21, 2020

The efficacy and safety of siponimod in the Russian population of patients with secondary progressive multiple sclerosis

The efficacy and safety of siponimod in the Russian population of patients with secondary progressive multiple sclerosis

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Published: January 15, 2020

Highly active multiple sclerosis: options for monoclonal antibody therapy

Highly active multiple sclerosis: options for monoclonal antibody therapy

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Published: January 15, 2020

Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia.

Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia.

Journal: PloS one
Published: December 03, 2018

Issues of the current terminology in multiple sclerosis

Issues of the current terminology in multiple sclerosis

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Published: August 31, 2018

Provision of alemtuzumab safety is one of the main components of pharmacovigilance

Provision of alemtuzumab safety is one of the main components of pharmacovigilance

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Published: August 31, 2018

What do we know about the pathology of gray matter in multiple sclerosis

What do we know about the pathology of gray matter in multiple sclerosis

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Published: August 31, 2018

The search for optimal decision in the treatment of multiple sclerosis: to improve adherence not reducing the efficacy

The search for optimal decision in the treatment of multiple sclerosis: to improve adherence not reducing the efficacy

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Published: January 24, 2018
Showing 1-12 of 26

Last Updated: 09/26/2026